Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes (T1D)
Type1 Diabetes Mellitus, Adiposity
About this trial
This is an interventional basic science trial for Type1 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
All Participants:
- Clinical diagnosis of T1D
- HbA1c ≤9%
- Diabetes duration of at least 12 months
Adolescents with T1D:
- Age 12-16 years
- BMI <75th for lean pediatric subjects, > 85th percentile for overweight/obese pediatric subjects;
- Tanner stage 2-5
- Parent able to provide written consent and participant able to provide assent
- Not meeting MRI safety criteria
- Claustrophobia that will prevent participation in the MRI
Lean, young adults with T1D:
- Age 18-24 years
- BMI 18.5-24.9 kg/m2
- Able to provide written consent.
Exclusion Criteria:
- Use of adjunctive diabetes medications
- Weight loss medications within the past six months
- Current psychiatric disorders, including eating disorders (DSM-V criteria)
- Known liver disease other than nonalcoholic hepatic steatosis
- Females who are pregnant or lactating
- Anemia or another medical condition that precludes participation in the study
Sites / Locations
- Yale Pediatric Diabetes Research Program
Arms of the Study
Arm 1
Arm 2
Arm 3
Other
Other
Other
Adolescent Overweight
Adolescent Typical
Young Adult
The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D that will receive a euglycemic hyperinsulinemic clamp with tracer enhancement.
The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement.
The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement